This is a firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Illumina, Inc. The $93,525.44 contract provides a 12-month silver support plan for two NextSeq 2000 sequencing systems. No set-aside was used. Illumina is a manufacturer and provider of genomic analysis instruments and reagents, and has previously received prime federal contracts and sub-awards from the NIH, CDC,...
This is a firm fixed price purchase order awarded by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Illumina, Inc. for a service agreement renewal and co-term for a NextSeq 2000 Silver Support Plan. The potential value of the award is $29,158.67, and the period of performance runs through July 4, 2024. Illumina is a for-profit manufacturer that has previously provided a range of sequencing systems, reagents, and support services to federal...
This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. government, to Illumina, Inc. for a service agreement for a NextSeq 2000 sequencing system. The total ceiling value of the contract is $48,209.00 and it has an ultimate completion date of December 15, 2025. This contract does not have a set-aside designation. Illumina is a manufacturer of genomic sequencing instruments and reagents, and...
This is a firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Illumina, Inc. for a NextSeq 2000 Silver Support Plan and Preventive Maintenance with a total ceiling value of $23,717.81. The award does not utilize any set-aside designations. Illumina is a manufacturer and provider of sequencing and array-based solutions for genetic and genomic analysis, and has received prior prime federal contract and sub-grant awards...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a firm-fixed-price purchase order to Illumina, Inc. for a NEXTSEQ 2000 SILVER SUPPORT PLAN. The potential value of the contract is $48,209.00, with a completion date of April 2, 2025. This contract is not set aside and is for the provision of sequencing and array-based solutions to support genomic analysis and life science research. Illumina, a for-profit...
This is a firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents. The contract provides a MiSeq Silver Support Plan with a ceiling value of $13,250.00 and an ultimate completion date of January 2, 2021. Illumina has a long history of providing sequencing systems and related products and services to support research and diagnostics across...
This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Illumina, Inc. for an Illumina Service Contract. The contract has a ceiling value of $72,973.00 and a period of performance through February 28, 2026. Illumina, a manufacturer of genomic sequencing and analysis instruments and reagents, will provide maintenance and support services for NIAID's Illumina sequencing systems, including NextSeq,...
This is a firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Illumina, Inc. for a renewal service agreement to support two Illumina NextSeq sequencing systems. The contract has a ceiling value of $74,756.41 and a period of performance through March 20, 2026. There is no set-aside designation for this award. Illumina is a manufacturer of genomic sequencing...
This is a firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The $24,999 contract is for a NEXTSEQ 2000 BRONZE SUPPORT PLAN (AMBIS 2259765) with a performance period through July 11, 2026. The contract does not utilize any set-aside designation. Illumina has been awarded numerous federal contracts and grants by agencies...
This is a $48,209 firm fixed price purchase order awarded by the National Institute on Deafness and Other Communication Disorders (NIDCD), a civilian agency within the National Institutes of Health (NIH), to Illumina, Inc. The contract provides a NEXT SEQ 2000 SILVER SUPPORT PLAN with a completion date of September 12, 2025. Illumina, a for-profit manufacturer of genomic sequencing and analysis equipment and reagents, has previously received other prime federal contracts and subcontracts from...